Avoro Capital Lifts Scribe Therapeutics Stake to 16.4%, Adding Open-Market Buys and Lock-Up Details
SCTX sits 30% above its 52-week low of $17.305.
Summary
Avoro Capital's Schedule 13D reveals a 16.4% stake in Scribe Therapeutics, built through IPO purchases, preferred conversions, and post-IPO open-market buys, with lock-up agreements limiting sales until late September 2026.
Key Events · Ownership and Investor Activity · SCTX
-
16.4% Beneficial Ownership Disclosed
Collectively, Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh own 3,088,888 shares, representing 16.37% of the outstanding total. The position consists of 697,650 converted preferred shares, 2,333,333 IPO shares at $15.00, and 57,905 open-market shares.
-
Post-IPO Open-Market Purchases
On July 24, Avoro bought 50,000 shares at $22.31, followed by 7,905 shares at $18.25 on July 28. The roughly $1.26 million in additional purchases signals continued accumulation above the IPO price.
-
Lock-Up Agreements Until September 28, 2026
Avoro's funds are subject to lock-up agreements that restrict sales of pre-IPO shares until September 28, 2026, though IPO and open-market shares are exempt.
-
Director Option Grant
Behzad Aghazadeh, a director and the portfolio manager, received an option to purchase 14,725 shares at $15.00, vesting over three years and aligning his interests with shareholders.
Analysis · SCTX · Life Sciences
Already known as a major IPO buyer, Avoro Capital Advisors and its affiliates now disclose a combined 16.4% beneficial ownership in Scribe Therapeutics. The Schedule 13D adds fresh granularity: 697,650 shares from preferred stock conversion, 2.33 million IPO shares at $15, and 57,905 open-market shares bought at $18.25–$22.31. It also reveals lock-up agreements extending to September 28, 2026, and a director option grant. The open-market purchases above the IPO price signal continued conviction, while the lock-up terms clarify near-term selling restrictions. This filing solidifies Avoro as the largest disclosed shareholder, with a stake worth roughly $69 million at today's price.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCTX was trading at $22.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $330.1M. The 52-week trading range was $17.31 to $22.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.